UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results.
The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below).
![](https://i0.wp.com/mind.uci.edu/wp-content/uploads/2022/12/Slide_25_0-1.jpg?resize=627%2C324&ssl=1)
Diverging Trajectories. People on lecanemab worsened more slowly on the CDR-SB than did people on placebo, resulting in a quarter less progression at 18 months. [Courtesy of Eisai.]